March 19, 2002
The study of Merck's experimental vaccine against AIDS is in its earliest stages, with clinical testing just beginning in human beings. The drug already is generating enthusiasm among scientists because of positive results in monkeys.
AIDS experts from across the country heard of the results at last month's Ninth Retrovirus Conference. "Of course, we need to collect more data and conclude our Phase I studies before we can determine how to move forward, but it's fair to say we are encouraged by the results to date," said John W. Shiver, senior director of Viral Vaccine Research at Merck.
At Albany Med, the focus is on finding healthy volunteers, ages 18 to 50, to take part in the new studies. So far, Albany Med has the second highest number of study participants, following the University of California at Sacramento, Piliero said.
The study involves 17 visits to Albany Med over an 18-month period. Participants receive a $50 stipend per visit. Interested persons should call 518-262-6330.
Times Union (Albany, N.Y.)
03.11.02; Sylvia Wood